This job has expired

Manager F P & A Systems

Employer
Oxford Biomedica UK Limited
Location
Oxford, Oxfordshire, United Kingdom
Salary
Competitive Salary
Closing date
Feb 13, 2024

View more

Job Role
Manager
Sector
Finance
Contract Type
Permanent
Hours
Full Time
We pride ourselves on our integrity. We do what’s right for our employees, patients, and partners, and so can you.

We are currently recruiting for a Financial Planning & Analysis Systems Manager to join the Finance team. The purpose of the role will be to manage, maintain and develop the FP&A system.

Our Finance team provide financial control, planning, and accountancy across the business.

Your responsibilities in this role would be:


Manage and maintain the Group’s FP&A system, including process flows, model accounting and output calculations, and to develop robust control procedures to ensure its ongoing utility.

Assist with and control the source data transfer into FP&A system to ensure full alignment and that the richness of data is sufficient to support analytical requirements.

Work with FP&A, the wider business and other finance colleagues to understand changes to the business and adapt the FP&A system accordingly to generate accurate financial forecast results.

Develop and prepare new and insightful reporting and analyses to assist management understanding of financial performance, improve decision making and monitor FP&A forecast accuracy so model improvements can be made.

Operation of all regular in-system forecasting cycles i.e. maintenance of in-system process flows, task deadlines, user level access and licensing requirements.

Support system users with troubleshooting queries, feeding back any suggested improvements within the FP&A team.

Share system knowledge with FP&A colleagues and other system users to maximize its utility while avoiding any confusion or duplication of effort.

We are looking for:
• CIMA/ACCA/ACA Qualified or similar

A good understanding of Financial Accounting practices

Experience of “Adaptive Insights” systems is preferred

Experience of working autonomously and closely as part of a team to deliver reliable financial information

Credible and able to build relationships with senior management across business functions as well as Group finance colleagues of all levels

Drive for results - a determined finisher, problem solver, creative in identifying and implementing pragmatic solutions, with a constant drive to add value

Good attention to detail and understanding of the importance of robust controls and the need for systems alignment to avoid dispute and confusion

Good Microsoft Office skills (especially MS Excel, PowerPoint & Teams)

About Us:
We are a quality and innovation-led cell and gene therapy CDMO with a mission to enable our clients to deliver life changing therapies to patients around the world.
Our innovative solutions and proven expertise allow our clients in the biotech and biopharma industry, to deliver life-saving therapies to reach even more patients.
The success of cell and gene therapy products transforms outcomes for millions of people suffering from some of the world’s worst diseases and medical conditions.

What’s in it for you:


Highly competitive reward package

Wellbeing programmes

Development opportunities

A 35-hour working week

Welcoming, friendly, supportive colleagues

A diverse and inclusive working environment

Our values are: Deliver Innovation, Be Inspiring and Have Integrity

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.

Collaborate. Contribute. Change lives.
No Agencies please.

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert